New hope for tough pancreatic cancer? early trial combines two drugs
NCT ID NCT06981806
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests two drugs (cosibelimab and balixafortide) together in people with advanced pancreatic cancer that has stopped responding to standard chemotherapy. The main goal is to find the safest dose and check for side effects. About 24 adults will take part in this single-center study.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cedars-Sinai Cancer at SOCC
Los Angeles, California, 90048, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an immunotherapy cocktail slow pancreatic cancer? a new trial aims to find out.
- Smart drug delivers chemo directly to pancreatic cancer cells
- Engineered T-Cells take aim at Hard-to-Treat pancreatic cancer
- Could a stomach drug help fight pancreatic cancer?
- New hope for tough pancreatic cancer? drug combo targets KRAS mutations
- Experimental vaccine combo takes on tough pancreatic cancer